Rachel Cohrs, STAT

Rachel Cohrs


Washington, DC, United States

Contact Rachel

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • STAT
  • The Dallas Morning News
  • The Sacramento Bee
  • TriCityHerald

Recent articles by Rachel:

PhRMA, once invincible in Washington, has lost its edge

PhRMA has a reputation in Washington for might, for money, and for scorched-earth tactics. Now, the once titanic lobbying powerhouse has lost its edge. → Read More

In a Republican-led House, anti-science probes top the agenda

Republicans just took the House. That means major Covid-19 investigations are coming. → Read More

A Democratic Senate improves the outlook for Biden health and science priorities, including key nominees

A Democratic Senate will make it much easier for Biden to get key health and science nominees confirmed, like an NIH director. It'll also mean less scrutiny for Anthony Fauci. → Read More

With Republicans on the verge of congressional control, science is on the line

Some of the most vocal critics of science agencies like the NIH and the CDC, including Sen. Rand Paul, are poised for power if Republicans take control of Congress. → Read More

Republican ideas to reform Medicare could rile health care industry

Republicans' ideas to reform Medicare could draw opposition from powerful health care industry interests. → Read More

Inside Michelle McMurry-Heath’s departure from BIO: Firings, internal clashes, and a pivotal job review

Michelle McMurry-Heath’s abrupt exit from BIO shocked the biotech industry. Here’s the inside story of how her departure unfolded. → Read More

After tough period for lobby, BIO chief Michelle McMurry-Heath goes on leave

Michelle McMurry-Heath, one of the most prominent faces of the drug industry in Washington, is on leave from her role as CEO of the Biotechnology Innovation Organization, the group confirmed on Sunday. → Read More

Drugmakers will be penalized if they hike prices on patients in private insurance market

Some have been concerned that drug pricing reforms that will save Medicare money could incentivize drugmakers to try to charge more to patients with other forms of insurance coverage. → Read More

Medicare tasks a senior adviser with staffing its new drug pricing division

Medicare has tasked a senior adviser at the agency with assembling a small army of bureaucrats to get its new drug price negotiation program up and running. → Read More

Medicare lays out the bureaucracy it will need to negotiate drug prices

New documents obtained by STAT outline how Medicare is planning to build out a sizable new bureaucratic infrastructure to handle its new power to negotiate drug prices. → Read More

Burning questions left unanswered about the latest Alzheimer’s therapy

Here are the burning questions left unanswered by the success of lecanemab, the latest Alzheimer’s treatment from Biogen and Eisai. → Read More

FDA funding negotiations heat up ahead of September deadline

Negotiations are intensifying over multibillion-dollar legislation to fund the Food and Drug Administration ahead of a September deadline. → Read More

Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use

Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use. → Read More

Cancer patient who devoted six years to drug pricing reform isn’t done yet

David Mitchell has filled an important void as a politically savvy patient advocate who was well-funded but didn’t take a penny from the pharmaceutical industry. → Read More

In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk

House Speaker Nancy Pelosi first pushed the House to pass Medicare drug pricing reform 15 years ago. This time, it’s actually going to be signed into law. → Read More

Here’s who Democrats’ drug pricing bill will actually help

Here's who's mostly likely to see benefits at the pharmacy counter, if Democrats pass their latest drug pricing plan into law. → Read More

In a massive victory for Democrats, Medicare is poised to negotiate drug prices

After a major vote Sunday, President Biden is on the verge of his own crowning health care achievement to call, in his words, a BFD. → Read More

Democrats dramatically narrow their ambitions for lowering insulin costs

Democrats’ high hopes to lower insulin costs for patients with insurance got downsized on Sunday, and now only Medicare patients will see relief at the pharmacy counter. → Read More

Democrats will have to limit their drug pricing reforms to Medicare to comply with Senate rules

Democrats will likely have to axe two provisions from their drug pricing plan to fit in with Senate rules, both of which would have brought down drug prices for people who get health insurance through their jobs. → Read More

Virtual Event: Democrats' Last Chance for Drug Pricing Reform?

STAT sits down with Sen. Ron Wyden and a panel of experts to talk about the latest developments from Capitol Hill and the White House. → Read More